Tumor-infiltrating lymphocytes for the treatment of metastatic cancer

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. / Geukes Foppen, M H; Donia, M; Svane, I M; Haanen, J B A G.

I: Molecular Oncology, Bind 9, Nr. 10, 12.2015, s. 1918-35.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Geukes Foppen, MH, Donia, M, Svane, IM & Haanen, JBAG 2015, 'Tumor-infiltrating lymphocytes for the treatment of metastatic cancer', Molecular Oncology, bind 9, nr. 10, s. 1918-35. https://doi.org/10.1016/j.molonc.2015.10.018

APA

Geukes Foppen, M. H., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015). Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Molecular Oncology, 9(10), 1918-35. https://doi.org/10.1016/j.molonc.2015.10.018

Vancouver

Geukes Foppen MH, Donia M, Svane IM, Haanen JBAG. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Molecular Oncology. 2015 dec.;9(10):1918-35. https://doi.org/10.1016/j.molonc.2015.10.018

Author

Geukes Foppen, M H ; Donia, M ; Svane, I M ; Haanen, J B A G. / Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. I: Molecular Oncology. 2015 ; Bind 9, Nr. 10. s. 1918-35.

Bibtex

@article{01de42a7f47b45bcaf333cef30413df8,

title = "Tumor-infiltrating lymphocytes for the treatment of metastatic cancer",

abstract = "Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma. Adoptive cell therapy using tumor-infiltrating lymphocytes is yet another, but highly promising, immunotherapeutic strategy for patients with metastatic melanoma. This review will discuss the development of TIL as a treatment option for melanoma, its mode of action and simplification over time, and the possibilities to expand this therapy to other types of cancer. Also, the future directions of TIL based therapies will be highlighted.",

author = "{Geukes Foppen}, {M H} and M Donia and Svane, {I M} and Haanen, {J B A G}",

year = "2015",

month = dec,

doi = "10.1016/j.molonc.2015.10.018",

language = "English",

volume = "9",

pages = "1918--35",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "10",

}

RIS

TY - JOUR

T1 - Tumor-infiltrating lymphocytes for the treatment of metastatic cancer

AU - Geukes Foppen, M H

AU - Donia, M

AU - Svane, I M

AU - Haanen, J B A G

PY - 2015/12

Y1 - 2015/12

N2 - Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma. Adoptive cell therapy using tumor-infiltrating lymphocytes is yet another, but highly promising, immunotherapeutic strategy for patients with metastatic melanoma. This review will discuss the development of TIL as a treatment option for melanoma, its mode of action and simplification over time, and the possibilities to expand this therapy to other types of cancer. Also, the future directions of TIL based therapies will be highlighted.

AB - Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma. Adoptive cell therapy using tumor-infiltrating lymphocytes is yet another, but highly promising, immunotherapeutic strategy for patients with metastatic melanoma. This review will discuss the development of TIL as a treatment option for melanoma, its mode of action and simplification over time, and the possibilities to expand this therapy to other types of cancer. Also, the future directions of TIL based therapies will be highlighted.

U2 - 10.1016/j.molonc.2015.10.018

DO - 10.1016/j.molonc.2015.10.018

M3 - Review

C2 - 26578452

VL - 9

SP - 1918

EP - 1935

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 10

ER -

ID: 162854492